Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study

Jacqueline S. Garcia(Dana-Farber Cancer Institute), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Tsila Zuckerman(Johannes Gutenberg University Mainz), Boaz Nachmias, Xenia Schmidt(AbbVie (United States)), Joshua F. Zeidner(University of North Carolina at Chapel Hill), Yanqing Xu(AbbVie (United States)), David Levitz(Montefiore Medical Center), Melissa Montez, Evan C. Chen(Dana-Farber Cancer Institute), D. Pollyea(University of Colorado Denver), Lee Mozessohn(Sunnybrook Health Science Centre), Kaitlyn Easson, Yakir Moshe(Tel Aviv University), Thomas W. LeBlanc(Duke University), Moshe Grunspan(Weizmann Institute of Science), M. Levesque-Leroux, Chia-Wei Lin, Annie Guérin(Group for Research in Decision Analysis), Kaylee Miu(AbbVie (United States)), Esprit Ma, Marina Konopleva(Albert Einstein College of Medicine), Kendra Sweet(Moffitt Cancer Center), Pankit Vachhani(University of Alabama at Birmingham), P Desai(Cornell University), Marin Xavier(Scripps MD Anderson Cancer Center), Maximilian Stahl(Yale Cancer Center), Sameem Abedin(Medical College of Wisconsin), Rebecca Burne, Catherine Lai(Georgetown University), Cat N. Bui(AbbVie (United States)), Eugene Baraka, Ofir Wolach(Tel Aviv University)
Leukemia & lymphoma/Leukemia and lymphoma
July 29, 2026
Cited by 0


Related Papers